HEXO Corp. (TSX:HEXO, NASDAQ:HEXO) (“HEXO” or the “Company“), a leading producer of high-quality cannabis products, today announced that, following shareholder approval of a consolidation of the common shares of the Company (“Common Shares“) on the basis of a range between two (2) and fourteen (14) existing pre-consolidation Common Shares for every one (1) post-consolidation Common Share (the “Consolidation“) at the annual and special meeting of the shareholders of the Company held on March 8, 2022, it has filed articles of amendment implementing the Consolidation on the basis of fourteen (14) existing pre-consolidation Common Shares for every one (1) post-consolidation Common Share.
Celularity And Verséa Ophthalmics Announce Exclusive U.S. Commercialization Agreement To Distribute Biovance And Biovance 3l Ocular For Ophthalmic Applications; Terms Of The Agreement Are Not Disclosed.
Celularity Inc. (NASDAQ:CELU) ("Celularity"), a biotechnology company developing placental-derived allogeneic cell therapies and biomaterial products, and Verséa Ophthalmics, LLC ("Verséa
